Loss of BAP1 in Pheochromocytomas and Paragangliomas Seems Unrelated to Genetic Mutations

This study documents that the loss of BAP1 nuclear expression is quite a frequent finding in PCC/PGL, suggesting a possible role ofBAP1 in the pathogenesis of these tumors. Gene mutations do not seem to be involved in this loss of expression, at least in most cases. Other genetic and epigenetic mechanisms need to be further investigated.
Source: Endocrine Pathology - Category: Pathology Source Type: research

Related Links:

Condition:   Malignant Neoplasm Interventions:   Drug: Fentanyl Sublingual Spray;   Drug: Morphine;   Other: Physical Performance Testing;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   D011471;   D064129;   D035683;   D009360;   D014408 Intervention:   Diagnostic Test: Periodic ARV7 and miRNA evaluation Sponsor:   Azienda Ospedaliero-Universitaria Careggi Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Locally Advanced Colon Cancer Intervention:   Combination Product: CAPECITABINE AND OXALIPLATIN Sponsor:   Universidad de León Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Patients With Metastatic Colorectal Cancer Interventions:   Drug: Fluoropyrimidine;   Drug: Bevacizumab Sponsor:   Centre Hospitalier Universitaire Dijon Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Breast Cancer Interventions:   Drug: Avelumab;   Drug: Aspirin;   Drug: Lansoprazole Sponsors:   The Christie NHS Foundation Trust;   University of Manchester Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Nutrition;   Physical Activity Interventions:   Behavioral: Intervention Physical Activity;   Other: Usual Care Sponsors:   University of North Carolina, Chapel Hill;   University of Texas Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Neutropenia;   Breast Cancer Interventions:   Drug: Eflapegrastim;   Drug: Docetaxel;   Drug: Cyclophosphamide Sponsor:   Spectrum Pharmaceuticals, Inc Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Melanoma;   Non-small Cell Lung Carcinoma (NSCLC);   Renal Cell Carcinoma (RCC);   Brain Metastases Intervention:   Combination Product: LITT + Pembrolizumab Sponsors:   University of Florida;   Monteris Medical Corporation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Metastatic or Unresectable Melanoma Interventions:   Drug: Nivolumab;   Drug: Talazoparib Sponsor:   Pauline Funchain Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Non Small Cell Lung Cancer;   Non Small Cell Lung Cancer Metastatic;   Healthy Intervention:   Sponsor:   Indiana University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Asbestosis | Cancer | Cancer & Oncology | Carcinoma | Genetics | Kidney Cancer | Melanoma | Men | Mesothelioma | Paraganglioma | Pathology | Pheochromocytoma | Renal Cell Carcinoma | Skin Cancer | Study